Can ‘Biosimilars’ Shake Up the U.S. Drug Market?

A.M. Edition for Feb. 1. One of America’s biggest-selling prescription drugs, AbbVie’s arthritis therapy Humira, is now facing its first competition in the U.S. in the form of a near-identical treatment from Amgen. WSJ health business editor Jonathan Rockoff explains how “biosimilar” drugs work and their potential to drive down prices for insurers and patients. Plus, why Ukraine hasn’t been a boon to U.S. defense companies. Luke Vargas hosts. Learn more about your ad choices. Visit megaphone.fm/adchoices